1045 related articles for article (PubMed ID: 17067309)
1. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
[TBL] [Abstract][Full Text] [Related]
2. B cell apoptosis accelerates the onset of murine lupus.
Trébéden-Nègre H; Weill B; Fournier C; Batteux F
Eur J Immunol; 2003 Jun; 33(6):1603-12. PubMed ID: 12778478
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
Early GS; Zhao W; Burns CM
J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
[TBL] [Abstract][Full Text] [Related]
4. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule.
Nakajima A; Azuma M; Kodera S; Nuriya S; Terashi A; Abe M; Hirose S; Shirai T; Yagita H; Okumura K
Eur J Immunol; 1995 Nov; 25(11):3060-9. PubMed ID: 7489744
[TBL] [Abstract][Full Text] [Related]
5. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice.
Wofsy D
J Immunol; 1986 Jun; 136(12):4554-60. PubMed ID: 3086436
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.
Finck BK; Chan B; Wofsy D
J Clin Invest; 1994 Aug; 94(2):585-91. PubMed ID: 8040314
[TBL] [Abstract][Full Text] [Related]
7. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
Wofsy D; Seaman WE
J Immunol; 1987 May; 138(10):3247-53. PubMed ID: 3106478
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model.
Ando DG; Sercarz EE; Hahn BH
J Immunol; 1987 May; 138(10):3185-90. PubMed ID: 2952711
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
Merino R; Iwamoto M; Fossati L; Izui S
J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
[TBL] [Abstract][Full Text] [Related]
10. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus.
Wen X; Zhang D; Kikuchi Y; Jiang Y; Nakamura K; Xiu Y; Tsurui H; Takahashi K; Abe M; Ohtsuji M; Nishimura H; Takatsu K; Shirai T; Hirose S
Eur J Immunol; 2004 Oct; 34(10):2740-9. PubMed ID: 15368290
[TBL] [Abstract][Full Text] [Related]
11. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody.
Ravirajan CT; Wang Y; Matis LA; Papadaki L; Griffiths MH; Latchman DS; Isenberg DA
Rheumatology (Oxford); 2004 Apr; 43(4):442-7. PubMed ID: 15024133
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice.
Zhou YB; Ye RG; Li YJ; Xie CM; Wu YH
Autoimmunity; 2008 Aug; 41(5):395-404. PubMed ID: 18568645
[TBL] [Abstract][Full Text] [Related]
13. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.
Carteron NL; Schimenti CL; Wofsy D
J Immunol; 1989 Mar; 142(5):1470-5. PubMed ID: 2521880
[TBL] [Abstract][Full Text] [Related]
14. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice.
Nakajima A; Hirose S; Yagita H; Okumura K
J Immunol; 1997 Feb; 158(3):1466-72. PubMed ID: 9013993
[TBL] [Abstract][Full Text] [Related]
15. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
16. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: analysis of T-cell lymphokine synthesis.
Sato MN; Minoprio P; Avrameas S; Ternynck T
Immunology; 1995 May; 85(1):26-32. PubMed ID: 7635519
[TBL] [Abstract][Full Text] [Related]
17. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis.
Ozmen L; Roman D; Fountoulakis M; Schmid G; Ryffel B; Garotta G
Eur J Immunol; 1995 Jan; 25(1):6-12. PubMed ID: 7843255
[TBL] [Abstract][Full Text] [Related]
18. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
19. Soluble human CD83 ameliorates lupus in NZB/W F1 mice.
Starke C; Steinkasserer A; Voll RE; Zinser E
Immunobiology; 2013 Nov; 218(11):1411-5. PubMed ID: 23886695
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin 10 in disseminated lupus erythematosus].
Emilie D
J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
